Summary
Metoprolol has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Hypertension would be drug repurposing rather than first-in-human development. This does not mean it is approved for Hypertension. ClinicalTrials.gov lists 7 registered trials linking Metoprolol to Hypertension: 5 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT00819104). The largest enrolment is 1900 participants (NCT00642096). Registration activity spans 2003 to 2015. The literature layer holds 14 publications for this pair: 5 Cochrane reviews, 3 meta-analyses, 1 systematic review and 5 clinical trial publications. Publication years run from 2014 to 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.
The RepurpOS disease-intelligence file for Essential Hypertension ranks 376 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Not well-characterized as population baseline; routinely framed as irreversible in clinical culture despite contrary trial evidence.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 74.0 (trials 24.0, literature 30.0, tier 15, approved bonus 5.0) |
| Registered trials | 7 total: 0 recruiting, 0 active / not yet recruiting, 5 completed, 2 other |
| Linked publications | 14 (5 Cochrane reviews, 5 clinical trial publications, 3 meta-analyses, 1 systematic review) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
| Linked via biomarker / target | ACE |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT00819104 | A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components 2008 | completed | Phase 4 | 402 |
| NCT02612298 | Efficacy and Safety of Arotinolol Hydrochloride on Morning Blood Pressure and Heart Rate 2015 | completed | Phase 4 | 198 |
| NCT00861016 | Efficacy and Safety of Metoprolol Succinate Prolonged-Release Tablet in Patients With Mild to Moderate Hypertension 2005 | completed | Phase 4 | 310 |
| NCT01238705 | Combined Antihypertensive Therapy and Sexual Dysfunction 2008 | status unknown | Phase 4 | 280 |
| NCT00642096 | Factorial Study of Metoprolol Succinate TOPROL-XL (324A) 2003 | completed | Phase 3 | 1,900 |
| NCT02336607 | The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients. 2005 | completed | Not applicable | 529 |
| NCT00152633 | Effect of Losartan on Retinal Endothelial Function in Patients With Essential Hypertension 2005 | withdrawn | PHASE2, PHASE3 | — |
Published literature
- Clinical trial publication Calcium Channel Blockade Versus β-Blockade for Hypertension in Heart Failure With Preserved Ejection Fraction: A Randomized Crossover TrialCohen JB, Hossain A, Chittams J et al. · Hypertension (Dallas, Tex. : 1979) · 2026 · PMID 42137945
- Clinical trial publication Effects of Two Allisartan Isoproxil-Based Antihypertensive Therapies on Sexual Function and Blood Pressure in Male Hypertensive Patients: A Single-Center, Open-Label, and Randomized Controlled TrialWang M, Chen J, Qi M et al. · Journal of clinical hypertension (Greenwich, Conn.) · 2025 · PMID 40965515
- Clinical trial publication [Efficacy of β-Blockers in Older Adults With Hypertension Combined With Vascular Dementia]Tian Z, Li W, Tian W et al. · Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025 · PMID 40964132
- Clinical trial publication Initial treatment with a single capsule containing half-dose quadruple therapy vs standard-dose dual therapy in hypertensive patients (QUADUAL): a randomized, blinded, crossover trialZhao X, Liu T, Yang Q et al. · BMC medicine · 2025 · PMID 39881316
- Meta-analysis Impact of antihypertensive treatment on cardiovascular event reduction in patients with asymptomatic carotid artery stenosis: a systematic review and meta-analysisPopat A, Pethe G, Yadav S et al. · The Pan African medical journal · 2025 · PMID 41323461
- Meta-analysis Antihypertensive therapy for pregnancy hypertension and implications for fetal and neonatal heart rate monitoring: A systematic review of randomized trials and observational studiesGaneshamoorthy A, Duke OF, Mistry HD et al. · Acta obstetricia et gynecologica Scandinavica · 2025 · PMID 40836392
- Clinical trial publication Comparison of the efficacy, safety, and tolerability of the FDC of telmisartan + bisoprolol with telmisartan + metoprolol succinate ER combination therapy for stage 1 and stage 2 hypertension: A double-blind, multicentric, phase-III clinical studyWander GS, Ram B, Kumar Sonkar S et al. · Indian heart journal · 2024 · PMID 38871219
- Cochrane review Position of Beta-blockers in the Treatment of Hypertension Today: An Indian ConsensusMohan JC, Roy DG, Ray S et al. · The Journal of the Association of Physicians of India · 2024 · PMID 39390868
- Meta-analysis Blood pressure lowering effects of β-blockers as add-on or combination therapy: A meta-analysis of randomized controlled trialsGuo QH, Zhu ZM, Feng YQ et al. · Journal of clinical hypertension (Greenwich, Conn.) · 2023 · PMID 36756690
- Cochrane review Comparative efficacy of β-blockers on mortality and cardiovascular outcomes in patients with hypertension: a systematic review and network meta-analysisZhang Y, Sun N, Jiang X et al. · Journal of the American Society of Hypertension : JASH · 2017 · PMID 28760243
- Systematic review Treatment Strategies for Paradoxical Hypertension Following Surgical Correction of Coarctation of the Aorta in ChildrenRoeleveld PP, Zwijsen EG · World journal for pediatric & congenital heart surgery · 2017 · PMID 28520538
- Cochrane review Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statementPaz MA, de-La-Sierra A, Sáez M et al. · Medicine · 2016 · PMID 27472680
- Cochrane review Blood pressure lowering efficacy of beta-1 selective beta blockers for primary hypertensionWong GW, Boyda HN, Wright JM · The Cochrane database of systematic reviews · 2016 · PMID 26961574
- Cochrane review Cochrane in context: pharmacological interventions for hypertension in childrenChaturvedi S, Lipszyc DH, Licht C et al. · Evidence-based child health : a Cochrane review journal · 2014 · PMID 25236306
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL, in this case via the biomarker or target ACE. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Metoprolol approved for Hypertension?
Metoprolol has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Hypertension would be drug repurposing rather than first-in-human development. This does not mean it is approved for Hypertension. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Metoprolol in clinical trials for Hypertension?
ClinicalTrials.gov lists 7 registered trials linking Metoprolol to Hypertension: 5 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT00819104). The largest enrolment is 1900 participants (NCT00642096). Registration activity spans 2003 to 2015.
What does the evidence show for Metoprolol in Hypertension?
Metoprolol has both completed registered trials and synthesis-level publications linked to Hypertension. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL, in this case via the biomarker or target ACE. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.